4 ms·
It's not their responsibility to do much of anything. But they're uniquely well positioned to push a lot of these things along, and it's a bit disappointing th
by apathy 19y ago
It's not their responsibility to do much of anything. But they're uniquely well positioned to push a lot of these things along, and it's a bit disappointing that they opt not to.
Plus, selling genomic information from your customers, in aggregate or not, is a rather evil thing to do given the potential for misuse. Hopefully there will not be any phenotypic information provided, but if they somehow manage to run out of money, who knows? Not all phenotypes require a whole organism, as I'm sure you know.
Also, I'm not saying "wait until we know everything there is to know". I'm saying "let's not go off half-cocked -- didn't we learn anything from the schizophrenia 'gene' study?". I am more than a little concerned about this.
- greendestiny 19y agoSelling the information along is another thing, I'm just responding to your comment I'm not saying 23andme are a great company. I've noticed myself that when I know a bit about an area, its easy to look at a particular company and see how far behind the research they are. 23andme are trying to take genome sequencing and give it to the masses. Is it very useful? probably not, but they are trying to hit a consumer price point - so doing a whole bunch of original research on genome sequencing, or making a sequencing chip of their own just isn't practical. A lot of Brin's money is and no doubt will go to good causes, but this isn't suppose to be a charity. Even if it doesn't take off, it's likely to be a positive thing for the personal genome industry not a negative.